Replies to post #531884 on NorthWest Biotherapeutics Inc (NWBO)

[hoffmann6383]

the post hoc totally redone clinical trial design is enough to raise serious questions

False. As linked here many times, this was not done 'post hoc' but before the trial was unblinded. This has been confirmed in presentations written or presented by Dr. Mulholland, Dr. Ashkan and Dr. Liau.

Add the confounding of the naive OS (double dosing)

False. The only confounding is that NWBO allowed crossovers to take DCVax-L. There is no confounding in counting beating hearts. I've linked relevant SEC filings multiple times. In fact, the FDA REQUIRED the crossover option.

regulators are going to have serious issues

False, the MHRA approved pediatric trials using the same design.

There are lots of false narratives out there on social media. It is important people do their own research.

[SkyLimit2022]

I think this excerpt might include some of the information that you’re looking for with regard to government agencies. NIH recently renewed their support and their support is ongoing. NIH and Merck are today funding the murcidencel Keytruda study underway at UCLA.








https://connect.uclahealth.org/2021/03/22/ucla-received-590-million-in-nih-funding-second-highest-total-for-academic-medical-centers-in-2020/

https://newsroom.ucla.edu/releases/nih-grant-lab-gene-cell-therapies

https://connect.uclahealth.org/2022/09/14/brain-cancer-discovery-clinical-trials/

[Dr Bala]

Thanks.